医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dalrada Health Presents VIA Cervical Cancer Screening Study Findings at 17th World Congress for Cervical Pathology and Colposcopy

2021年05月04日 PM09:00
このエントリーをはてなブックマークに追加


 

SAN DIEGO

Dalrada Corporation (OTCQB: DFCO, “Dalrada”) is pleased to announce to its shareholders and the public that Dalrada Health’s abstract on the topic of Combined Pap Smear and Visual Inspection with Acetic Acid-Based Screening for Cervical Cancer in a Tertiary Care Hospital has been accepted by IFCPC World Congress. Dalrada Health’s Chief Medical Officer, Dr. Payal Keswarpu, is a presenter who will share clinical study results at the 17th World Congress for Cervical Pathology and Colposcopy. This year’s event marks the first Virtual IFCPC World Congress to be held online July 1st – 5th, 2021. Industry experts from more than 42 countries are anticipated to participate.

Cervical cancer is the fourth most common cancer in women, according to the World Health Organization. The organization’s website states, “When diagnosed, cervical cancer is one of the most successfully treatable forms of cancer, as long as it is detected early and managed effectively.”

The use of Dalrada Health’s patented cerVIA™ kits by a healthcare professional in a primary healthcare setting simplifies procedures for rapid management of multiple aspects to achieve early detection of cervical cancer. In positive cases, a biopsy can be taken immediately providing more time for healthcare providers to develop treatment protocols and avoid multiple visits for the patient, especially during a pandemic.

Based on the World Health Organization’s recommended procedure for conducting a visual inspection with acetic acid for cervical cancer screening in low resource settings, Dalrada Health’s cerVIA™ kits contain all the necessary elements required for the procedure to be conducted by a healthcare professional in a primary healthcare setting. Dalrada Health’s cerVIA™ kits are manufactured in FDA or ISO-approved facilities ensuring quality control for consistent validation processes.

Further studies indicate that VIA screening, implemented by trained healthcare professionals with products of sustained quality assurance, is an effective method for cervical cancer screening in low to middle-income countries.

Brian Bonar, CEO of Dalrada, states, “Early detection of cervical cancer can save countless lives around the world. Dalrada Health supports reducing the high mortality rate from cervical cancer with primary prevention, affordable and effective screening, and treatment programs.”

For additional information, visit https://cerVIAtest.com

About Dalrada Health
A wholly-owned subsidiary of Dalrada Corporation, Dalrada Health is focused on solving health problems around the world. The company develops products and services that address the unmet needs of consumers due to accessibility, affordability, or availability. With operations in the U.S., Malaysia, and India, Dalrada Health can reach underserved markets through strong partnerships and the development of efficient supply chains. Dalrada Health is committed to solving universal health problems through improved methodologies resulting in products and services that benefit the global marketplace. For details, visit https://dalradahealth.com

About Dalrada (DFCO)
Dalrada Corporation (OTCQB: DFCO, “Dalrada”) solves real-world problems by producing innovation-focused and technologically centered solutions on a global level. Delivering next-generation manufacturing, engineering, and healthcare products and services designed to propel growth, Dalrada is a team of industry experts and an organization built upon a strong foundation of financial capital. The Company and its subsidiaries are positioned for stable long-term growth through intelligent market research, sound business acumen, and established operational infrastructure. For more information, visit www.dalrada.com or call 1-858-283-1253.

Disclaimer
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management’s current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the U.S. Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005518/en/

CONTACT

Media Contact

Denise Mahaffey

858.283.1253

inquiries@dalrada.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 亚马逊与美国国家安全委员会携手开展业界首创合作项目,以解决美国常见的工伤问题
  • Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline
  • 片肺換気中の高酸素血症介在疾患の罹患率にORiを指針とする酸素需要評価が及ぼす影響についての新研究
  • セルトリオン、抗COVID-19モノクローナル抗体治療剤「Regdanvimab(CT-P59)」の グローバル第3相臨床試験結果を発表
  • 沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台,树立高分辨质谱性能新标杆